Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use
2004733 citationsSebastian J. Padayatty, He Sun et al.Annals of Internal Medicineprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Hugh D. Riordan
Since
Specialization
Citations
This map shows the geographic impact of Hugh D. Riordan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugh D. Riordan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugh D. Riordan more than expected).
This network shows the impact of papers produced by Hugh D. Riordan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugh D. Riordan. The network helps show where Hugh D. Riordan may publish in the future.
Co-authorship network of co-authors of Hugh D. Riordan
This figure shows the co-authorship network connecting the top 25 collaborators of Hugh D. Riordan.
A scholar is included among the top collaborators of Hugh D. Riordan based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Hugh D. Riordan. Hugh D. Riordan is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Casciari, Joseph J, Hugh D. Riordan, Jorge R. Miranda-Massari, & Michael J. González. (2005). Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs.. PubMed. 24(2). 145–50.18 indexed citations
Miranda-Massari, Jorge R., et al.. (2004). Intravenous ascorbic acid as a treatment for severe jellyfish stings.. PubMed. 23(2). 125–6.4 indexed citations
5.
Padayatty, Sebastian J., He Sun, Yaohui Wang, et al.. (2004). Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Annals of Internal Medicine. 140(7). 533–537.733 indexed citations breakdown →
Riordan, Neil H, Hugh D. Riordan, Nina Mikirova, et al.. (2004). Cell membrane fatty acid composition differs between normal and malignant cell lines.. PubMed. 23(2). 103–6.29 indexed citations
11.
Mikirova, Nina, et al.. (2003). Detection of energy metabolism level in cancer patients by fluorescence emission from serum. 18(1). 9–24.5 indexed citations
12.
James, Jackson, et al.. (2002). Sixteen-year history with high dose intravenous vitamin C treatment for various types of cancer and other diseases. 17(2). 117–119.3 indexed citations
13.
González, Michael J., Hugh D. Riordan, & Jorge R. Miranda-Massari. (2002). Vitamin C and oxidative DNA damage revisited. 17(4). 225–228.3 indexed citations
14.
Riordan, Neil H, Joseph J Casciari, Yan Zhu, et al.. (2002). Effects of a high molecular mass Convolvulus arvensis extract on tumor growth and angiogenesis.. PubMed. 21(4). 323–8.22 indexed citations
Riordan, Neil H, et al.. (2000). Clinical and Experimental Experiences with Intravenous Vitamin C.29 indexed citations
17.
Riordan, Hugh D., et al.. (1998). HIGH-DOSE INTRAVENOUS VITAMIN C IN THE TREATMENT OF A PATIENT WITH RENAL CELL CARCINOMA OF THE KIDNEY. 13(2). 72–73.25 indexed citations
18.
González, Michael J., Neil H Riordan, & Hugh D. Riordan. (1998). Antioxidants as Chemopreventive Agents for Breast Cancer.3 indexed citations
Jackson, James, et al.. (1991). Comparison of two cytotoxic food sensitivity tests.. PubMed. 10(2). 20–1.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.